Global Ischemic Stroke Pipeline Report 2015
M2 - Thu May 14, 5:26AM CDT
Research and Markets (http://www.researchandmarkets.com/research/w6cj3m/ischemic_stroke) has announced the addition of the "Ischemic Stroke - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Ischemic Stroke, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Ischemic Stroke and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AB Science - Acorda Therapeutics, Inc. - Acticor Biotech - advanceCor GmbH - AGY Therapeutics, Inc. - Angion Biomedica Corp. - AstraZeneca PLC - Athersys, Inc. - Biogen Idec Inc. - BioTime, Inc. - D-Pharm Ltd. - Daiichi Sankyo Company, Limited - DiaMedica Inc. - Digna Biotech, S.L. - Genervon Biopharmaceuticals, LLC - GlaxoSmithKline plc - International Stem Cell Corporation - Laboratoires Pierre Fabre SA - Lumosa Therapeutics Co., Ltd. - MediaPharma s.r.l. - Mesoblast Limited - Mitsubishi Tanabe Pharma Corporation - Neuralstem, Inc. - Neurotec Pharma SL - NeuroVive Pharmaceutical AB - Panacea Pharmaceuticals, Inc. - Pharmicell Co., Ltd. - PhytoHealth Corporation - SanBio, Inc. - Saneron CCEL Therapeutics, Inc. - Simcere Pharmaceutical Group - Stemedica Cell Technologies, Inc. - Vicore Pharma AB - Virogenomics, Inc. For more information visit http://www.researchandmarkets.com/research/w6...mic_stroke
BIIB: 391.24 (-3.11), ACOR: 30.04 (+0.14), GSK: 44.77 (-0.22), AZN: 69.29 (-0.81), ATHX: 1.27 (-0.01), CUR: 1.70 (-0.04)
Global Gastric Cancer Pipeline Report 2015
M2 - Thu May 14, 5:22AM CDT
Research and Markets (http://www.researchandmarkets.com/research/527p3s/gastric_cancer) has announced the addition of the "Gastric Cancer - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Gastric Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Gastric Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Gastric Cancer Overview - Therapeutics Development - Gastric Cancer - Therapeutics under Development by Companies - Gastric Cancer - Therapeutics under Investigation by Universities/Institutes - Gastric Cancer - Pipeline Products Glance - Gastric Cancer - Products under Development by Companies - Gastric Cancer - Products under Investigation by Universities/Institutes - Gastric Cancer - Companies Involved in Therapeutics Development - Gastric Cancer - Therapeutics Assessment - Drug Profiles - Gastric Cancer - Recent Pipeline Updates - Gastric Cancer - Dormant Projects - Gastric Cancer - Discontinued Products - Gastric Cancer - Product Development Milestones - Appendix Companies Mentioned: Partial List - AB Science - Chipscreen Biosciences Ltd - Chugai Pharmaceutical Co., Ltd. - Covagen AG - DAE HWA Pharmaceutical Co., Ltd. - Daiichi Sankyo Company, Limited - Galena Biopharma, Inc. - Genentech, Inc. - GlaxoSmithKline plc - GlycoNex Inc. - Glycotope GmbH - ISU ABXIS Co.,Ltd. - Jiangsu Hengrui Medicine Co., Ltd. - Jiangsu Kanion Pharmaceutical Co., Ltd. - Kadmon Corporation, LLC - Millennium Pharmaceuticals, Inc. - Molecular Targeting Technologies, Inc. - MSM Protein Technologies, Inc. - NanoCarrier Co., Ltd. - NeoPharm Co., Ltd. - Novartis AG - Regulon Inc. - Rexahn Pharmaceuticals, Inc. - Richter Gedeon Nyrt. - Sanofi - Sareum Holdings plc - SentoClone International AB - Sequella, Inc. - Zymeworks Inc. For more information visit http://www.researchandmarkets.com/research/52...ric_cancer
RNN: 0.71 (+0.01), GALE: 1.35 (-0.01), GSK: 44.77 (-0.22), NVS: 103.75 (-0.15)
Idiopathic (Essential) Hypertension Therapeutics Pipeline Review 2015
M2 - Wed May 06, 8:19AM CDT
Research and Markets (http://www.researchandmarkets.com/research/ftwwp9/idiopathic) has announced the addition of the "Idiopathic (Essential) Hypertension - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Idiopathic (Essential) Hypertension, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Idiopathic (Essential) Hypertension and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Bayer AG - Chong Kun Dang Pharmaceutical Corp. - Daiichi Sankyo Company, Limited - Eli Lilly and Company - Jiangsu Hengrui Medicine Co., Ltd. - Lee's Pharmaceutical Holdings Limited - PhaseBio Pharmaceuticals, Inc. - Quantum Genomics SA - Takeda Pharmaceutical Company Limited Drug Profiles - (amlodipine besylate azilsartan medoxomil hydrochlorothiazide) - (amlodipine besylate candesartan) - (nifedipine candesartan cilexetil) - azilsartan medoxomil - carvedilol phosphate ER - - carvedilol SR - CS-3150 - LY-2623091 - PB-1120 - QGC-001 - rostafuroxin For more information visit http://www.researchandmarkets.com/research/ftwwp9/idiopathic About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
LLY: 72.90 (-0.16)
Pulmonary Embolism Pipeline Review 2015 - Analysis of 4 Companies & 6 Drug Profiles
M2 - Mon Apr 27, 11:23AM CDT
Research and Markets (http://www.researchandmarkets.com/research/f85q3d/pulmonary) has announced the addition of the "Pulmonary Embolism - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Pulmonary Embolism, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Pulmonary Embolism and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Bayer AG - Bristol-Myers Squibb Company - Daiichi Sankyo Company, Limited - F. Hoffmann-La Roche Ltd. Drug Profiles - apixaban - edoxaban tosylate - rivaroxaban - Small Molecule to Inhibit Cyclooxygenase and Glycoprotein IIb/IIIa for Pulmonary Embolism and Hematological Disorders - SMTP-7 - TRX-1 For more information visit http://www.researchandmarkets.com/research/f85q3d/pulmonary
BMY: 67.64 (+0.19)
Global Dermatitis Pipeline Review 2015
M2 - Mon Apr 27, 4:33AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7sjwj3/dermatitis) has announced the addition of the "Dermatitis - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Dermatitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Dermatitis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Dermatitis Overview - Therapeutics Development - Dermatitis - Therapeutics under Development by Companies - Dermatitis - Therapeutics under Investigation by Universities/Institutes - Dermatitis - Pipeline Products Glance - Dermatitis - Products under Development by Companies - Dermatitis - Products under Investigation by Universities/Institutes - Dermatitis - Companies Involved in Therapeutics Development - Dermatitis - Therapeutics Assessment - Drug Profiles - Dermatitis - Recent Pipeline Updates - Dermatitis - Dormant Projects - Dermatitis - Discontinued Products - Dermatitis - Product Development Milestones - Appendix Companies Mentioned - Partial List - AlbireoPharma - Amorepacific Corporation - Anacor Pharmaceuticals, Inc. - AnaMar AB - AnaptysBio, Inc. - AnGes MG, Inc. - Aquinox Pharmaceuticals Inc. - arGEN-X BV - Biomar Microbial Technologies - Blueberry Therapeutics Ltd - Brickell Biotech, Inc. - Bristol-Myers Squibb Company - Celgene Corporation - Celsus Therapeutics Plc - ChemoCentryx, Inc. - China Biologic Products, Inc. - ChironWells GmbH - Chugai Pharmaceutical Co., Ltd. - Circassia Pharmaceuticals plc - Convoy Therapeutics, Inc. - Creabilis SA - Daiichi Sankyo Company, Limited - Dermira Inc. - Eisai Co., Ltd. - EpiPharm AG - F. Hoffmann-La Roche Ltd. - FAES Farma SA - Foamix Pharmaceuticals Ltd. - Fountain Biopharma Inc. - GlaxoSmithKline plc For more information visit http://www.researchandmarkets.com/research/7sjwj3/dermatitis
AQXP: 7.34 (-0.17), FOMX: 11.41 (+0.09), GSK: 44.77 (-0.22), BMY: 67.64 (+0.19), CBPO: 101.56 (+0.67), DERM: 14.97 (-0.07), CCXI: 7.21 (-0.09), ANAC: 62.37 (-1.71), CLTX: 0.55 (+0.01), CELGZ: 2.60 (-0.10)
Daiichi Sankyo's Once-Daily Lixiana(R) (edoxaban) Receives Positive CHMP Opinion for the Prevention of Stroke and Systemic Embolism in Non-Valvular Atrial Fibrillation and for the Treatment and Prevention of Recurrent Venous Thromboembolism in Europe
PR Newswire Europe - Fri Apr 24, 6:56AM CDT
TOKYO, April 24, 2015 /PRNewswire/ --
Pulmonary Embolism Therapeutic Development and Pipeline Market Review H1 2015 Available at RnRMarketResearch.com
PRWeb - Tue Apr 21, 2:30PM CDT
The report "Pulmonary Embolism - Pipeline Review, H1 2015" provides comparative analysis on the therapeutic development for Pulmonary Embolism. The report strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Complete report with TOC is available @ http://www.rnrmarketresearch.com/pulmonary-em...eport.html .
BMY: 67.64 (+0.19)
Tetanus Therapeutic Development and Pipeline Market Review H1 2015 Available at RnRMarketResearch.com
PRWeb - Wed Apr 15, 9:31AM CDT
The report "Tetanus - Pipeline Review, H1 2015" provides comparative analysis on the therapeutic development for Tetanus. Tetanus is a acute infectious disease of humans and other animals, caused by toxins produced by the bacillus Clostridium tetani and characterized by rigidity and spasms of the voluntary muscles. The initial symptoms of tetanus include irritable and sore muscles. Muscles also get stiff and become cramped and body starts to feel tired. Swallowing food also becomes a problem. The report strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Complete report with TOC is available @ http://www.rnrmarketresearch.com/tetanus-pipe...eport.html .
SVA: 5.36 (-0.25), NVS: 103.75 (-0.15)
Daiichi Sankyo's Once-Daily Lixiana(R) (edoxaban) Approved for the Prevention of Stroke and Systemic Embolism in Non-Valvular Atrial Fibrillation and for the Treatment and Prevention of Recurrent Venous Thromboembolism in Switzerland
PR Newswire Europe - Wed Apr 15, 1:01AM CDT
TOKYO, April 15, 2015 /PRNewswire/ --
Daiichi Sankyo, Inc. and Asubio Pharmaceuticals, Inc. Merge
PR Newswire - Wed Apr 01, 7:00AM CDT
Daiichi Sankyo, Inc., the US subsidiary of Daiichi Sankyo Company, Ltd, announced today that it will merge with its US-based sister company, Asubio Pharmaceuticals, Inc. As a result, Asubio Pharmaceuticals, Inc. projects will be integrated into the Daiichi Sankyo global development organization, led by Mahmoud Ghazzi, MD, PhD.
Anorexia Nervosa Global Clinical Trials Review, H1, 2015
M2 - Wed Apr 01, 6:22AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7tzf2t/anorexia_nervosa) has announced the addition of the "Anorexia Nervosa Global Clinical Trials Review, H1, 2015" report to their offering. Anorexia Nervosa Global Clinical Trials Review, H1, 2015 provides data on the Anorexia Nervosa clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Anorexia Nervosa. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Anorexia Nervosa. Reasons to buy - Understand the dynamics of a particular indication in a condensed manner - Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more - Obtain discontinued trial listing for trials across the globe - Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies Top Companies Participating in Anorexia Nervosa Therapeutics Clinical Trials - Sky Growth Acquisition Corporation - Medionics International Inc - Daiichi Sankyo Company, Limited - Cannabics Pharmaceuticals, Inc. - Bristol-Myers Squibb Company - BioGaia AB - AstraZeneca PLC - Arjun Healthcare - Anaborex, Inc. For more information visit http://www.researchandmarkets.com/research/7t...ia_nervosa
AZN: 69.29 (-0.81), BMY: 67.64 (+0.19)
Bile Duct Cancer (Cholangiocarcinoma) Global Clinical Trials Review, H1, 2015
M2 - Wed Apr 01, 5:52AM CDT
Research and Markets (http://www.researchandmarkets.com/research/h5z2hq/bile_duct_cancer) has announced the addition of the "Bile Duct Cancer (Cholangiocarcinoma) Global Clinical Trials Review, H1, 2015" report to their offering. This report provides elemental information and data relating to the clinical trials on Bile Duct Cancer (Cholangiocarcinoma). It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Bile Duct Cancer (Cholangiocarcinoma). Reasons to buy - Understand the dynamics of a particular indication in a condensed manner - Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more - Obtain discontinued trial listing for trials across the globe - Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies Top Companies Participating in Bile Duct Cancer (Cholangiocarcinoma) Therapeutics Clinical Trials - Sanofi - Eli Lilly and Company - AstraZeneca PLC - GlaxoSmithKline plc - OncoTherapy Science, Inc. - Daiichi Sankyo Company, Limited - CellAct Pharma GmbH - C. H. Boehringer Sohn AG & Co. KG - Astellas US Holding, Inc. - Agios Pharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/h5...uct_cancer
AZN: 69.29 (-0.81), LLY: 72.90 (-0.16), AGIO: 112.78 (-0.69), GSK: 44.77 (-0.22)
Liposarcoma Global Clinical Trials Review, H1, 2015
M2 - Wed Apr 01, 5:51AM CDT
Research and Markets (http://www.researchandmarkets.com/research/fgbx2p/liposarcoma) has announced the addition of the "Liposarcoma Global Clinical Trials Review, H1, 2015" report to their offering. This report provides elemental information and data relating to the clinical trials on Liposarcoma. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Liposarcoma. Reasons to buy - Understand the dynamics of a particular indication in a condensed manner - Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more - Obtain discontinued trial listing for trials across the globe - Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies Top Companies Participating in Liposarcoma Therapeutics Clinical Trials - Pfizer Inc. - Zeltia, S.A. - Johnson & Johnson - F. Hoffmann-La Roche Ltd. - Novartis AG - Merck & Co., Inc. - Sanofi - Daiichi Sankyo Company, Limited For more information visit http://www.researchandmarkets.com/research/fg...iposarcoma
JNJ: 102.30 (+0.47), PFE: 33.99 (+0.05), MRK: 60.23 (+0.45), NVS: 103.75 (-0.15)
Non-Rhabdomyosarcoma Global Clinical Trials Review, H1, 2015
M2 - Wed Apr 01, 5:50AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hbxmkx/nonrhabdomyosarco) has announced the addition of the "Non-Rhabdomyosarcoma Global Clinical Trials Review, H1, 2015" report to their offering. This report provides elemental information and data relating to the clinical trials on Non-Rhabdomyosarcoma. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Non-Rhabdomyosarcoma. Reasons to buy - Understand the dynamics of a particular indication in a condensed manner - Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more - Obtain discontinued trial listing for trials across the globe - Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies Top Companies Participating in Non-Rhabdomyosarcoma Therapeutics Clinical Trials - Pfizer Inc. - Zeltia, S.A. - GlaxoSmithKline plc - Johnson & Johnson - F. Hoffmann-La Roche Ltd. - Novartis AG - Merck & Co., Inc. - Daiichi Sankyo Company, Limited For more information visit http://www.researchandmarkets.com/research/hb...domyosarco
JNJ: 102.30 (+0.47), PFE: 33.99 (+0.05), MRK: 60.23 (+0.45), GSK: 44.77 (-0.22), NVS: 103.75 (-0.15)
U.S. launch of Movantik underway
Seeking Alpha - at Seeking Alpha - Tue Mar 31, 8:39AM CDT
SGYP: 3.52 (+0.04), PGNX: 5.67 (+0.02), AZN: 69.29 (-0.81), SLXP: 172.96 (+0.15), NKTR: 11.13 (+0.20)
Polycystic Kidney Disease Global Clinical Trials Review, H1, 2015
M2 - Tue Mar 31, 4:15AM CDT
Research and Markets (http://www.researchandmarkets.com/research/zf6s4z/polycystic_kidney) has announced the addition of the "Polycystic Kidney Disease Global Clinical Trials Review, H1, 2015" report to their offering. Polycystic Kidney Disease Global Clinical Trials Review, H1, 2015" provides data on the Polycystic Kidney Disease clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Polycystic Kidney Disease. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Polycystic Kidney Disease. Reasons to buy - Understand the dynamics of a particular indication in a condensed manner - Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more - Obtain discontinued trial listing for trials across the globe - Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies Top Companies Participating in Polycystic Kidney Disease Therapeutics Clinical Trials - Otsuka Holdings Co., Ltd. - Pfizer Inc. - Kadmon Corporation, LLC - Daiichi Sankyo Company, Limited - XORTX Pharma Corp. - Novartis AG - GLG Pharma LLC For more information visit http://www.researchandmarkets.com/research/zf...tic_kidney
PFE: 33.99 (+0.05), NVS: 103.75 (-0.15)
Proteinuria Global Clinical Trials Review, H1, 2015
M2 - Tue Mar 31, 3:48AM CDT
Research and Markets (http://www.researchandmarkets.com/research/j9t788/proteinuria) has announced the addition of the "Proteinuria Global Clinical Trials Review, H1, 2015" report to their offering. Proteinuria Global Clinical Trials Review, H1, 2015" provides data on the Proteinuria clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Proteinuria. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Proteinuria. Reasons to buy - Understand the dynamics of a particular indication in a condensed manner - Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more - Obtain discontinued trial listing for trials across the globe - Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies Top Companies Participating in Proteinuria Therapeutics Clinical Trials - Novartis AG - Merck & Co., Inc. - Pfizer Inc. - Mallinckrodt plc - Actavis plc - AstraZeneca PLC - Daiichi Sankyo Company, Limited - Cinkate Corporation - C. H. Boehringer Sohn AG & Co. KG - Abbott Laboratories For more information visit http://www.researchandmarkets.com/research/j9...roteinuria
ABT: 48.71 (+0.04), PFE: 33.99 (+0.05), MRK: 60.23 (+0.45), AZN: 69.29 (-0.81), NVS: 103.75 (-0.15)
Cough Therapeutics Pipeline Review 2015 Featuring 34 Companies
M2 - Wed Mar 25, 12:00PM CDT
Research and Markets (http://www.researchandmarkets.com/research/qpt4xp/cough_pipeline) has announced the addition of the "Cough - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Cough, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cough and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Afferent Pharmaceuticals, Inc. - Ahn-Gook Pharmaceutical Co., Ltd. - Alitair Pharmaceuticals, Inc. - Ario Pharma Ltd - AUS Bio Limited - Beijing Minhai Biotechnology Co., Ltd - Beijing Tiantan Biological Products Co., Ltd. - Bharat Biotech International Limited - Biological E. Limited - Daewoong Pharmaceutical Co., Ltd. - Daiichi Sankyo Company, Limited - DBV Technologies S.A. - GlaxoSmithKline plc - Glenmark Pharmaceuticals Ltd. - Green Cross Corporation - Hanmi Pharmaceuticals, Co. Ltd. - Hydra Biosciences, Inc. - Hyundai Pharmaceutical Co., Ltd. - Indian Immunologicals Limited - LG Life Sciences, Ltd. - NanoBio Corporation - Neos Therapeutics, Inc. - Novartis AG - Orbis Biosciences, Inc. - Panacea Biotec Limited - Sanofi - Sanofi Pasteur SA - Serum Institute of India Limited - Sinovac Biotech Ltd. - Synthetic Biologics, Inc. For more information visit http://www.researchandmarkets.com/research/qp...h_pipeline
SYN: 1.87 (-0.02), GSK: 44.77 (-0.22), SVA: 5.36 (-0.25), NVS: 103.75 (-0.15)
This Market Could Grow 6250% in 10 Years
Cheryl Swanson, The Motley Fool - Motley Fool - Mon Mar 23, 4:44PM CDT
Big Pharma just looked into its future... and saw a whole new era dawning. Last year, 32 large-molecule drugs, called biologics, with combined sales of $51 billion, lost patent protection. This year, another $28 billion worth will join them. ...
JNJ: 102.30 (+0.47), BAX: 69.36 (+0.32), C: 54.24 (-0.36), PFE: 33.99 (+0.05), AMGN: 162.36 (+0.38), ABBV: 65.99 (+0.02), HSP: 88.10 (-0.08), NVS: 103.75 (-0.15), CHRS: 24.05 (+1.42)
AstraZeneca inks U.S. co-commercialization deal for OIC med
Seeking Alpha - at Seeking Alpha - Thu Mar 19, 11:14AM CDT
AZN: 69.29 (-0.81), NKTR: 11.13 (+0.20)